Informação jurídica inteligente
 Brasil | +55 (11) 31 81 77 29

União Química gears up to make Russian vaccine in Brazil

Document Citado por Related
Vincent

Drugmaker União Química will file a request for emergency use of Russian vaccine Sputnik V with the health regulator Anvisa next week. CEO Fernando de Castro Marques says that, if greenlighted, the company may offer the vaccine in Brazil.

The vaccine was developed by Russia's Gamaleya Institute. União Química is the Russian government's production partner in Latin America.

"The production is likely to start by the second half of January. The cell bank has already arrived to the country. With this, we can start the vaccine production," Mr. Castro Marques said.

The vaccine Sputnik V will be produced in União Química's biotechnology unit Bthek, in Brasília. When operating at full capacity, the plant will be able to produce 8 million doses a month. "Once the production starts, we will be able to supply countries that already cleared its use, such as Argentina."

The cell bank and the growth medium - key inputs in the manufacturing process - are included in the technology transfer agreement between Russian Direct Investment Fund (RDIF) and União Química for the local production of the immunizing agent against covid-19. Packaging will occur at the company's unit in Guarulhos, São Paulo.

According to União Química, Sputnik V is the first registered vaccine in the world based on a human adenovirus platform. "We will supply the vaccine to all markets, both public and private. We will have products for the National Immunization Plan (PNI) if the vaccine is approved by Anvisa," Mr. Castro Marques said.

The executive emphasized that seven executives of União Química will...

Para continuar a ler

PEÇA SUA AVALIAÇÃO

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT